| Not Yet Recruiting | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma NCT07514819 | St. Jude Children's Research Hospital | N/A |
| Recruiting | Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma NCT07283731 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarc NCT06670976 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiothe NCT07436364 | Thomas Jefferson University | EARLY_Phase 1 |
| Recruiting | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization NCT05264974 | University of Florida | Phase 1 |
| Recruiting | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631 | Novartis Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | Prospective Phase I/II Study Evaluating the Safety and Efficacy of Preoperative Carbon Ion Radiotherapy in Pat NCT07250334 | Yonsei University | N/A |
| Recruiting | Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma NCT07243626 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-oper NCT07049848 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas NCT07052383 | Tcelltech Inc. | Phase 1 |
| Recruiting | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma NCT06962072 | Amsterdam UMC | — |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease NCT06332274 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Recruiting | Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma NCT06905132 | Medical University of South Carolina | Phase 2 |
| Active Not Recruiting | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec NCT06660810 | John Rieth | Phase 2 |
| Not Yet Recruiting | Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study NCT06264505 | Power Life Sciences Inc. | — |
| Not Yet Recruiting | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897 | ECOG-ACRIN Cancer Research Group | N/A |
| Not Yet Recruiting | Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy NCT06726512 | University Medical Center Groningen | N/A |
| Recruiting | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma NCT06537596 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 1 |
| Recruiting | 68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas NCT06500065 | Ohio State University Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor NCT06551896 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma NCT06506838 | Guangdong Provincial People's Hospital | Phase 4 |
| Withdrawn | A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma NCT06494787 | Sarcoma Oncology Research Center, LLC | Phase 2 |
| Recruiting | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI NCT06333314 | UNICANCER | Phase 2 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. NCT06514313 | Yizhuo Zhang | Phase 2 |
| Withdrawn | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) NCT06252727 | University of California, Davis | Phase 1 |
| Not Yet Recruiting | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors NCT06500091 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | Pre-operative Hypofractionated Proton Therapy NCT05917301 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Active Not Recruiting | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants NCT06566092 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma NCT05813327 | Washington University School of Medicine | Phase 1 |
| Recruiting | Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patie NCT06409013 | Mayo Clinic | — |
| Recruiting | IVIM & OLINK in Sarcoma NCT05950594 | University Health Network, Toronto | Phase 2 |
| Recruiting | Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma NCT05679921 | Yonsei University | Phase 2 |
| Recruiting | Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard NCT05926700 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Active Not Recruiting | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients NCT05821231 | Institut Claudius Regaud | Phase 1 |
| Recruiting | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) NCT05712694 | Polaris Group | Phase 3 |
| Recruiting | A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ NCT06022159 | Institut Claudius Regaud | Phase 2 |
| Recruiting | Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With NCT06129903 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma P NCT06050434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Recruiting | 5-Day Preoperative Radiation for Soft Tissue Sarcoma NCT06087861 | Stanford University | Phase 2 |
| Withdrawn | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer NCT05655598 | Brown University | Phase 1 |
| Recruiting | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Su NCT05621668 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma NCT05776667 | Medical University of South Carolina | N/A |
| Recruiting | Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy NCT05944913 | Centre Leon Berard | N/A |
| Recruiting | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105 | Innolake Biopharm | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors NCT06171282 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Active Not Recruiting | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma NCT05886634 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03) NCT05938374 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Withdrawn | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cance NCT05582031 | Translational Research in Oncology | Phase 2 |
| Unknown | Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma NCT05684874 | Centre Leon Berard | N/A |
| Recruiting | A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma NCT05755113 | QBiotics Group Limited | Phase 2 |
| Recruiting | Use of GnRHa During Chemotherapy for Fertility Protection NCT05328258 | Kenny Rodriguez-Wallberg | Phase 3 |
| Recruiting | Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities NCT06760221 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma NCT05718778 | Henan Cancer Hospital | N/A |
| Completed | Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach NCT05420727 | John O. Prior | Phase 1 |
| Unknown | Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma NCT05656144 | Peking University Cancer Hospital & Institute | Phase 2 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Withdrawn | Gemcitabine With Ascorbate Including Adolescents NCT04877587 | David Dickens | EARLY_Phase 1 |
| Active Not Recruiting | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS NCT05688280 | Immunophotonics, Inc. | Phase 1 / Phase 2 |
| Unknown | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma NCT05448820 | Tracon Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Completed | An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing NCT05560009 | Mayo Clinic | — |
| Unknown | The Effects of Observer Presence and Type on Patients' Perception of Exercise in Patients With Soft Tissue Sar NCT05596565 | Istanbul Medeniyet University | N/A |
| Withdrawn | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors NCT04791228 | Children's National Research Institute | Phase 2 |
| Unknown | Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma NCT05602415 | Ruijin Hospital | Phase 2 |
| Unknown | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma NCT06117878 | Base Therapeutics (Shanghai) Co., Ltd. | EARLY_Phase 1 |
| Completed | Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) NCT05497843 | Chipscreen Biosciences, Ltd. | Phase 2 |
| Unknown | Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas NCT05518526 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 1 / Phase 2 |
| Recruiting | Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT) NCT05761054 | Azienda Ospedaliero-Universitaria Careggi | N/A |
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; NCT05432193 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Unknown | Phase II Study of TAEST16001 in Soft Tissue Sarcoma NCT05549921 | Sun Yat-sen University | Phase 2 |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherap NCT05526417 | Mayo Clinic | N/A |
| Completed | PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or NCT06413095 | Presage Biosciences | EARLY_Phase 1 |
| Recruiting | A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma NCT05301764 | Lyvgen Biopharma Holdings Limited | Phase 1 / Phase 2 |
| Terminated | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors NCT05229601 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas NCT05109494 | University of Wisconsin, Madison | Phase 2 |
| Terminated | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed C NCT05355753 | C4 Therapeutics, Inc. | Phase 1 |
| Recruiting | Genomic Risk in Retroperitoneal Sarcoma NCT06436846 | Fox Chase Cancer Center | — |
| Unknown | A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubici NCT05121350 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Recruiting | INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy NCT03175718 | Dr. J. Werier | N/A |
| Unknown | Wide Excision of Soft Tissue Sarcomas in Combination With Interstitial Radiation Therapy NCT05057195 | Blokhin's Russian Cancer Research Center | N/A |
| Unknown | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. NCT05189483 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01) NCT05224934 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | HIFU Ablation of Soft Tissue Sarcoma NCT05111964 | Oxford University Hospitals NHS Trust | N/A |
| Recruiting | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced NCT04995003 | Baylor College of Medicine | Phase 1 |
| Suspended | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types NCT05000294 | University of Florida | Phase 1 / Phase 2 |
| Completed | Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resista NCT06202599 | Peking University People's Hospital | — |
| Unknown | Fruquintinib in the Treatment of Soft Tissue Sarcoma NCT05142631 | Fudan University | Phase 2 |
| Recruiting | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma NCT04383119 | Italian Sarcoma Group | Phase 2 |
| Recruiting | tTF-NGR Randomized Study - STS NCT05597917 | Universität Münster | Phase 3 |
| Recruiting | Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients NCT05051059 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Active Not Recruiting | The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patien NCT05741944 | Leiden University Medical Center | N/A |
| Recruiting | Adriamycin and Ifosfamide Combined With Sintilimab NCT04589754 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours NCT04969835 | Avacta Life Sciences Ltd | Phase 1 |
| Recruiting | Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions NCT04946357 | University Hospital Heidelberg | N/A |
| Unknown | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas NCT05131386 | Grupo Espanol de Investigacion en Sarcomas | Phase 2 |
| Recruiting | Exercise and Soft Tissue Sarcoma NCT04921917 | Duke University | N/A |
| Unknown | Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma NCT05747521 | Henan Cancer Hospital | N/A |
| Recruiting | Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma NCT04776525 | Oslo University Hospital | Phase 2 |
| Recruiting | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Proje NCT03967834 | Institut Claudius Regaud | N/A |
| Completed | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers NCT05697198 | Labcorp Corporation of America Holdings, Inc | — |
| Completed | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients NCT04811196 | University Health Network, Toronto | Phase 1 |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors NCT04579757 | Hutchmed | Phase 1 / Phase 2 |
| Terminated | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid NCT04725331 | Transgene | Phase 1 / Phase 2 |
| Unknown | Predictive Models of Treatment Responses and Survival Outcomes in Patients With Soft Tissue Sarcoma NCT05171413 | West China Hospital | — |
| Active Not Recruiting | Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) NCT04634227 | University of Iowa | EARLY_Phase 1 |
| Unknown | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma NCT04910126 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Toripalimab Combined With CAV/IE Regimen NCT04589741 | Sun Yat-sen University | Phase 2 |
| Unknown | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue S NCT04606108 | Sun Yat-sen University | Phase 2 |
| Recruiting | Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma NCT04307277 | Institut Claudius Regaud | Phase 3 |
| Recruiting | Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma NCT04577014 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Prehabilitation Soft-Tissue Sarcoma of Lower Limb NCT04518488 | McGill University | N/A |
| Active Not Recruiting | TVEC and Preop Radiation for Sarcoma (8 ml Dose) NCT04599062 | John Rieth | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sar NCT04733183 | Philogen S.p.A. | Phase 2 |
| Terminated | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities NCT04037527 | Wake Forest University Health Sciences | Phase 1 |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Withdrawn | Identification of Surgical Management of Lymph Node Basins and Surgical Practice Patterns Among Sarcoma Surgeo NCT04553744 | M.D. Anderson Cancer Center | — |
| Unknown | TAEST16001 in the Treatment of Soft Tissue Sarcoma NCT04318964 | Sun Yat-sen University | Phase 1 |
| Active Not Recruiting | Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs NCT04288375 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma T NCT02923778 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resec NCT04166006 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Surveillance AFter Extremity Tumor surgerY NCT03944798 | McMaster University | N/A |
| Terminated | Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery NCT03916796 | Washington University School of Medicine | N/A |
| Active Not Recruiting | Molecular Profiling of Advanced Soft-tissue Sarcomas NCT03784014 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 3 |
| Active Not Recruiting | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors NCT04165330 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration NCT04040205 | Medical College of Wisconsin | Phase 2 |
| Completed | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma NCT04118166 | Kristen Ganjoo | Phase 2 |
| Active Not Recruiting | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS NCT04032964 | Philogen S.p.A. | Phase 1 |
| Unknown | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma NCT04012827 | Sun Yat-sen University | Phase 2 |
| Terminated | A Safety Study of SGN-CD47M in Patients With Solid Tumors NCT03957096 | Seagen Inc. | Phase 1 |
| Recruiting | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWO NCT04181970 | Grupo Espanol de Investigacion en Sarcomas | — |
| Completed | High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas NCT03508726 | Mohammed Milhem | Phase 1 / Phase 2 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nerv NCT03899792 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Active Not Recruiting | Hypofractionated Radiotherapy for Soft Tissue Sarcomas NCT03972930 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma NCT04126811 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors NCT03960060 | Shanghai PerHum Therapeutics Co., Ltd. | Phase 1 |
| Unknown | Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma NCT03890068 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | APX005M and Doxorubicin in Advanced Sarcoma NCT03719430 | Alexander Z. Wei, MD | Phase 2 |
| Terminated | FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas NCT03730077 | University of Pennsylvania | Phase 1 |
| Unknown | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and U NCT04239443 | Hunan Cancer Hospital | Phase 2 |
| Unknown | Circulating Tumor DNA in Soft Tissue Sarcoma NCT03818412 | University Health Network, Toronto | N/A |
| Terminated | Liposomal Bupivacaine (Exparel) in Sarcomas NCT03867188 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Unknown | Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy NCT03792542 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Completed | LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) NCT03725605 | Lytix Biopharma AS | Phase 2 |
| Completed | Incisional Negative Pressure Wound Therapy for Resection of Soft Tissue Tumors NCT03900078 | Ruhr University of Bochum | N/A |
| Completed | Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma NCT03602833 | Royal Marsden NHS Foundation Trust | Phase 1 / Phase 2 |
| Terminated | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma NCT03524898 | Swiss Cancer Institute | Phase 1 / Phase 2 |
| Completed | US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors NCT03452644 | Istituto Ortopedico Rizzoli | — |
| Terminated | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable NCT03520959 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Terminated | Gemcitabine Plus Ascorbate for Sarcoma in Adults NCT03468075 | Mohammed Milhem, MBBS | Phase 2 |
| Completed | Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma NCT03217266 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Unknown | NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma NCT03462316 | Sun Yat-sen University | Phase 1 |
| Completed | Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma NCT03514381 | Institut Claudius Regaud | Phase 4 |
| Completed | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcom NCT03449901 | Washington University School of Medicine | Phase 2 |
| Unknown | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953 | Institut Bergonié | Phase 1 / Phase 2 |
| Completed | FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With B NCT03913806 | University Medical Center Groningen | Phase 1 / Phase 2 |
| Active Not Recruiting | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Ca NCT03449108 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma NCT03338959 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Enrolling By Invitation | LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology NCT03244020 | Massachusetts General Hospital | Phase 4 |
| Active Not Recruiting | RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3 NCT03375437 | Centre Leon Berard | N/A |
| Completed | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies NCT03365791 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma NCT02982486 | Assaf-Harofeh Medical Center | Phase 2 |
| Recruiting | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients Wi NCT04650984 | Philogen S.p.A. | Phase 3 |
| Completed | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. NCT03345485 | Mundipharma Research Limited | Phase 1 / Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Sof NCT03283696 | Eli Lilly and Company | Phase 1 |
| Withdrawn | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia NCT03007771 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) NCT02910895 | The Netherlands Cancer Institute | N/A |
| Recruiting | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial S NCT03016819 | Advenchen Laboratories, LLC | Phase 3 |
| Active Not Recruiting | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma NCT03114527 | Fox Chase Cancer Center | Phase 2 |
| Completed | A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue S NCT03126591 | Eli Lilly and Company | Phase 1 |
| Unknown | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma NCT03168061 | NanoCarrier Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma NCT03116529 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Completed | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas NCT03277924 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Completed | Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study NCT03546127 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas NCT03042819 | University Health Network, Toronto | Phase 1 |
| Completed | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Car NCT03085225 | Institut Bergonié | Phase 1 |
| Unknown | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. NCT03242382 | Grupo Espanol de Investigacion en Sarcomas | Phase 2 |
| Unknown | A Phase II Study of Apatinib in STS Patients NCT03064243 | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Phase 2 |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Terminated | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas NCT02987959 | Fox Chase Cancer Center | Phase 2 |
| Terminated | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors NCT02784795 | Eli Lilly and Company | Phase 1 |
| Completed | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma NCT02945800 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma NCT02783599 | Eli Lilly and Company | Phase 1 |
| Terminated | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis NCT02890368 | Pfizer | Phase 1 |
| Active Not Recruiting | Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma NCT04055753 | Fox Chase Cancer Center | — |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Terminated | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer NCT02795819 | Virginia Commonwealth University | Phase 1 |
| Unknown | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma NCT03096912 | Assaf-Harofeh Medical Center | Phase 2 |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Completed | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer NCT02632448 | Esperas Pharma Inc. | Phase 1 / Phase 2 |
| Unknown | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Lip NCT02571829 | Hadassah Medical Organization | Phase 2 |
| Completed | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma NCT02659020 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall NCT02634710 | Medical College of Wisconsin | N/A |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Recruiting | In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma NCT02811523 | University Health Network, Toronto | Phase 1 |
| Completed | A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma NCT02787642 | Institut Bergonié | Phase 1 |
| Unknown | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma ( NCT02630368 | Institut Bergonié | Phase 1 / Phase 2 |
| Completed | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sar NCT02451943 | Eli Lilly and Company | Phase 3 |
| Terminated | Safety Study of MGD009 in B7-H3-expressing Tumors NCT02628535 | MacroGenics | Phase 1 |
| Completed | Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors NCT02192333 | Fred Hutchinson Cancer Center | N/A |
| Completed | Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma NCT02367924 | PharmaMar, Spain | — |
| Completed | TVEC and Preop Radiation for Sarcoma (4 ml Dose) NCT02453191 | University of Iowa | Phase 1 / Phase 2 |
| Completed | Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be NCT02527304 | Albert Einstein College of Medicine | N/A |
| Withdrawn | Stereotactic Radiosurgery for Soft Tissue Sarcoma NCT02706171 | The Cooper Health System | N/A |
| Unknown | Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) NCT02449343 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not NCT02300545 | Washington University School of Medicine | Phase 2 |
| Terminated | National Swiss Sarcoma Cohort Study NCT02775799 | Balgrist University Hospital | — |
| Unknown | PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS NCT03268772 | Fudan University | Phase 2 |
| Completed | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas NCT02301039 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Terminated | Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas NCT02547376 | University Hospitals, Leicester | — |
| Completed | Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma NCT02672527 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma NCT02267083 | Gem Pharmaceuticals | Phase 2 |
| Terminated | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma NCT02255110 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Completed | Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma NCT02204111 | GWT-TUD GmbH | — |
| Completed | Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) NCT02398058 | Italian Sarcoma Group | Phase 1 |
| Completed | Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease NCT02080897 | Duke University | — |
| Unknown | Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma NCT01904565 | Kantonsspital Aarau | Phase 1 / Phase 2 |
| Completed | Dendritic Cell Vaccine for Children and Adults With Sarcoma NCT01803152 | Macarena De La Fuente, MD | Phase 1 |
| Completed | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer NCT01896778 | Roswell Park Cancer Institute | N/A |
| Unknown | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors NCT01807468 | Samsung Medical Center | Phase 2 |
| Completed | A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall NCT01819831 | Loma Linda University | N/A |
| Completed | Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas NCT01802125 | Children's Oncology Group | — |
| Completed | Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma NCT01719744 | University Health Network, Toronto | Phase 2 |
| Unknown | Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma NCT01812018 | Peng Yuan | Phase 2 |
| Completed | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tiss NCT01861951 | Hannover Medical School | Phase 2 |
| Completed | Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria NCT01650077 | Centre Oscar Lambret | — |
| Withdrawn | Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas NCT01663090 | Dana-Farber Cancer Institute | N/A |
| Completed | Cathepsin Activatable Fluorescent Probe NCT01626066 | David Kirsch | Phase 1 |
| Terminated | Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarco NCT01612481 | Centre Oscar Lambret | Phase 2 |
| Completed | Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma NCT01498835 | Heidelberg University | Phase 1 |
| Completed | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previous NCT01458249 | Eisai Co., Ltd. | Phase 2 |
| Completed | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors NCT01505569 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiate NCT01438554 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma NCT01259375 | University of Utah | Phase 2 |
| Completed | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Adva NCT01440088 | Threshold Pharmaceuticals | Phase 3 |
| Completed | Evaluating Bacterial Response in Sarcoma Management Using Fluorescence Imaging NCT02270086 | University Health Network, Toronto | — |
| Completed | High Precision RT For Soft-Tissue Sarcoma NCT01389050 | University Health Network, Toronto | Phase 2 |
| Terminated | HYPAZ: Hypertension Induced by Pazopanib NCT01392352 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 |
| Completed | Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sar NCT01327885 | Eisai Inc. | Phase 3 |
| Withdrawn | Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma NCT01296659 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Completed | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma NCT01303094 | Centre Oscar Lambret | Phase 2 |
| Completed | Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) NCT01347034 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide NCT01299506 | PharmaMar | — |
| Completed | Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology NCT01696760 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas NCT01106872 | Mohammed M Milhem | Phase 1 |
| Completed | A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas NCT01140737 | Sheffield Teaching Hospitals NHS Foundation Trust | Phase 2 |
| Completed | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue NCT01168791 | Alaunos Therapeutics | Phase 3 |
| Completed | Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden NCT01136824 | University of Pittsburgh | — |
| Completed | Pharmacokinetic Study of Doxorubicin in Children With Cancer NCT01095926 | University Hospital Muenster | Phase 2 |
| Completed | Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (ST NCT00918489 | Heidelberg University | Phase 2 |
| Completed | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors NCT00931931 | Timothy Cripe | Phase 1 |
| Terminated | Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma NCT01055028 | Stanford University | Phase 2 |
| Completed | Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and NCT01575951 | University of Utah | N/A |
| Completed | Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-tr NCT01136499 | Centre Leon Berard | Phase 2 |
| Terminated | Identification and Characterization of Molecular Markers in Musculoskeletal Tumors NCT02199938 | Balgrist University Hospital | — |
| Completed | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers NCT01005797 | Medical University of South Carolina | Phase 1 |
| Completed | Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma NCT00876031 | University Hospital Tuebingen | Phase 3 |
| Unknown | Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas NCT00998361 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 2 |
| Completed | Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extrem NCT00864032 | University of California, Davis | Phase 1 / Phase 2 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Unknown | Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma NCT00753727 | Australasian Sarcoma Study Group | Phase 1 / Phase 2 |
| Terminated | Phase II Study of Doxorubicin and Avastin® in Sarcoma. NCT00755261 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sa NCT00742963 | ImmunoGenesis | Phase 1 / Phase 2 |
| Terminated | Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma NCT00717522 | Celgene | Phase 2 |
| Unknown | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sa NCT00718484 | Alaunos Therapeutics | Phase 2 |
| Completed | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types NCT00633789 | Bristol-Myers Squibb | Phase 2 |
| Completed | Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma NCT01102608 | Grupo Espanol de Investigacion en Sarcomas | Phase 2 |
| Completed | Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma NCT00626704 | Amgen | Phase 1 / Phase 2 |
| Completed | Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide NCT00629343 | Columbia University | Phase 1 |
| Unknown | Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma NCT00541840 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Unknown | A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and T NCT00790244 | Oslo University Hospital | Phase 2 |
| Completed | Collecting and Storing Tissue From Young Patients With Cancer NCT00898755 | Children's Oncology Group | — |
| Completed | Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma NCT00441467 | Eleison Pharmaceuticals LLC. | Phase 2 |
| Completed | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced NCT00413192 | Eisai Inc. | Phase 2 |
| Completed | Dalteparin in Preventing DVT in Participants With Cancer NCT00525057 | M.D. Anderson Cancer Center | N/A |
| Completed | Bevacizumab and Radiation Therapy for Sarcomas NCT00356031 | Massachusetts General Hospital | Phase 2 |
| Completed | External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma NCT00365872 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer NCT00288444 | Emory University | Phase 1 |
| Completed | Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma NCT01382030 | Heidelberg University | Phase 2 |
| Completed | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma NCT00102609 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | Metastatic or Refractory Soft Tissue Sarcomas and Metronomic Cyclophosphamide: Further Assessment of Efficacy NCT06216990 | Centre Hospitalier Universitaire de Besancon | — |
| Completed | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma NCT00580320 | Virginia Commonwealth University | Phase 1 |
| Completed | Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study NCT00611078 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas NCT00087997 | Synta Pharmaceuticals Corp. | Phase 2 |
| Completed | Study of Low Dose CT in Sarcoma Patients NCT00188422 | University Health Network, Toronto | Phase 1 |
| Terminated | Huntsman Biopsy Study NCT00615329 | State University of New York - Upstate Medical University | — |
| Active Not Recruiting | Radiation Therapy to Treat Musculoskeletal Tumors NCT00186992 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma NCT00502411 | M.D. Anderson Cancer Center | Phase 1 |